Arvinas, Inc. (ARVN) - What Are Brokerages Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Nine analysts rate Arvinas “Moderate Buy,” including five buys and one strong buy, with an average 12-month price target of $15.40.
• Recent research targets range from $10.00 at Morgan Stanley to $18.00 at BTIG, while Wedbush maintained a neutral rating after raising its target to $12.00.
• Institutional ownership is high at 95.19%. Shares opened at $7.86, near the lower end of their 52-week range, while the company’s latest quarterly results exceeded expectations with $249.7 million in revenue and $2.58 EPS.

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $15.40.

Several research firms have issued reports on ARVN. Evercore set a $14.00 price objective on Arvinas in a research note on Monday, August 10th. Morgan Stanley set a $10.00 target price on Arvinas in a research note on Monday, August 10th. Wall Street Zen raised shares of Arvinas from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. BTIG Research reissued a "buy" rating and issued a $18.00 target price on shares of Arvinas in a research note on Tuesday, August 4th. Finally, Wedbush boosted their price target on Arvinas from $11.00 to $12.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th.

Institutional Trading of Arvinas

Institutional investors and hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Arvinas in the third quarter worth about $26,000. Profund Advisors LLC boosted its holdings in shares of Arvinas by 191.2% during the 3rd quarter. Profund Advisors LLC now owns 76,112 shares of the company's stock worth $589,000 after buying an additional 49,977 shares in the last quarter. State of Wyoming lifted its stake in Arvinas by 178.2% in the third quarter. State of Wyoming now owns 41,893 shares of the company's stock valued at $324,000 after purchasing an additional 26,833 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Arvinas by 16.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,930 shares of the company's stock valued at $89,000 after purchasing an additional 1,661 shares in the last quarter. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in Arvinas in the third quarter worth $45,000. Institutional investors and hedge funds own 95.19% of the company's stock.

Arvinas Price Performance

Shares of ARVN opened at $7.86 on Monday. Arvinas has a 52-week low of $6.74 and a 52-week high of $14.51. The company has a 50-day simple moving average of $8.10 and a 200-day simple moving average of $9.70. The company has a market capitalization of $507.13 million, a PE ratio of 78.61 and a beta of 1.81.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $2.95. The business had revenue of $249.70 million for the quarter, compared to analyst estimates of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%. The business's revenue was up 1014.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.84) EPS. On average, research analysts anticipate that Arvinas will post 0.05 EPS for the current year.

About Arvinas

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company's proprietary PROTAC® protein degrader platform is designed to direct the body's natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.